New data is emerging about the neuroprotective properties of masitinib, an inhibitor of the c-kit tyrosine kinase, which is currently in Phase III clinical trials for ALS. The drug targets mast cells and macrophages and exhibits anti-inflammatory properties. AB Science, the Paris, France-based pharmaceutical company that developed the drug, recently announced the publication of preclinical results on the effects of masitinib treatment in ischemic stroke. The findings, published in the Oct 26 edition of Naunyn-Schmiedeberg’s Archives of Pharmacology, demonstrate that masitinib reduces brain ischemia induced by experimental stroke, likely by reducing permeability of the blood brain barrier.
Click here to read more about these new results.Share this: